KZIA
Kazia Therapeutics·NASDAQ
--
--(--)
--
--(--)
0.58 / 10
Underperform
Financial analysis yields an inadequate rating (0.6/10). Key positives include a high fixed assets turnover ratio (28,052.7) and an inventory turnover ratio (110.999), both indicating efficient asset utilization. However, concerns arise from a low current assets turnover ratio (0.0206) and a net profit to total profit ratio of 92.22%, which, despite the high percentage, falls in the lowest quartile and historically correlates with negative returns. Gross profit margin is strong at 100%, but the overall financial picture remains subdued, supporting a selective fundamental assessment.
Analysis Checks(3/5)
Inventory turnover ratio
Value111.00
Score2/3
Weight117.70%
1M Return-2.63%
Value111.00
Score2/3
Weight117.70%
1M Return-2.63%
Current assets turnover ratio
Value0.02
Score0/3
Weight84.86%
1M Return-1.88%
Value0.02
Score0/3
Weight84.86%
1M Return-1.88%
Net profit / Total profit (%)
Value92.22
Score0/3
Weight13.72%
1M Return-0.30%
Value92.22
Score0/3
Weight13.72%
1M Return-0.30%
Gross profit margin (%)
Value100.00
Score2/3
Weight-76.71%
1M Return1.47%
Value100.00
Score2/3
Weight-76.71%
1M Return1.47%
Fixed assets turnover ratio
Value28052.73
Score3/3
Weight-39.56%
1M Return0.86%
Value28052.73
Score3/3
Weight-39.56%
1M Return0.86%
Inventory turnover ratio
Value111.00
Score2/3
Weight117.70%
1M Return-2.63%
Value111.00
Score2/3
Weight117.70%
1M Return-2.63%
Gross profit margin (%)
Value100.00
Score2/3
Weight-76.71%
1M Return1.47%
Value100.00
Score2/3
Weight-76.71%
1M Return1.47%
Current assets turnover ratio
Value0.02
Score0/3
Weight84.86%
1M Return-1.88%
Value0.02
Score0/3
Weight84.86%
1M Return-1.88%
Fixed assets turnover ratio
Value28052.73
Score3/3
Weight-39.56%
1M Return0.86%
Value28052.73
Score3/3
Weight-39.56%
1M Return0.86%
Net profit / Total profit (%)
Value92.22
Score0/3
Weight13.72%
1M Return-0.30%
Value92.22
Score0/3
Weight13.72%
1M Return-0.30%
Is KZIA fundamentally strong?
- KZIA scores 0.58/10 on fundamentals and holds a Premium valuation at present. Backed by its 0.00% ROE, -1089.01% net margin, -4.82 P/E ratio, -12.03 P/B ratio, and 63.37% earnings growth, these metrics solidify its Underperform investment rating.
